MedElevator Войти в исследования
← Поиск публикаций

DOI 10.14740/cr2109

Медицинская библиотека · Cardiology research · 2025

Anti-Oxidative Effect of Dapagliflozin, a Selective Sodium Glucose Transporter-2 Inhibitor, for Cardio-Renal Protection in Patients With Heart Failure With Reduced Ejection Fraction.

Tsudome Riku, Suematsu Yasunori, Tashiro Kohei, Ideishi Akihito, Miyazaki Midori, Yano Yuiko, Arimura Tadaaki, Hirata Tetsuo, Fujimi Kanta, Miura Shin-Ichiro

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Selective sodium glucose transporter-2 inhibitor (SGLT2i) has cardio-renal protective effects via osmotic diuresis and natriuresis, and other pleiotropic effects, such as anti-oxidative, anti-fibrotic, and anti-senescence effects, have been suggested. However, those pleiotropic effects have not yet been fully elucidated in a clinical study.

METHODS

We investigated the effects of SGLT2i in patients with heart failure with reduced ejection fraction (HFrEF). Twenty-five HFrEF patients who were initially treated with dapagliflozin from 2021 to 2023 at Fukuoka University Hospital were enrolled and we investigated their baseline characteristics, medications, clinical laboratory examination findings, echocardiography findings, and additional pleiotropic serum markers before administration of dapagliflozin and 6 months later.

RESULTS

The patients were 67.0 ± 13.6 years old, 64.0% were male, and their body mass index was 24.0 ± 4.5 kg/m2. Only four patients (16.0%) had diabetes mellitus. With regard to medications, 64.0%, 76.0%, and 60.0% were already taking renin-angiotensin aldosterone system inhibitors, beta-blockers, and mineralocorticoid receptor antagonists, respectively, and these medications did not change significantly for 6 months. After treatment with dapagliflozin for 6 months, serum brain natriuretic peptide, left ventricular ejective function, hemoglobin, and urinary N-acetyl-β-D-glycosaminidase were significantly improved. In addition, high-sensitivity C-reactive protein and oxidative stress markers including myeloperoxidase, matrix metalloproteinase-1, and matrix metalloproteinase-9 significantly improved, while anti-fibrosis and anti-senescence markers did not.

CONCLUSIONS

Dapagliflozin had anti-oxidative effects in patients with HFrEF, in addition to cardio-renal protective effects. These anti-oxidative effects could be related to the cardio-renal protective effects of SGLT2i, even in a clinical setting.

Для цитирования: Tsudome Riku, Suematsu Yasunori, Tashiro Kohei, Ideishi Akihito, Miyazaki Midori, Yano Yuiko, Arimura Tadaaki, Hirata Tetsuo, Fujimi Kanta, Miura Shin-Ichiro. Anti-Oxidative Effect of Dapagliflozin, a Selective Sodium Glucose Transporter-2 Inhibitor, for Cardio-Renal Protection in Patients With Heart Failure With Reduced Ejection Fraction.. Cardiology research. 2025. DOI: 10.14740/cr2109.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.